[
  {
    "ts": null,
    "headline": "U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season",
    "summary": "RAHWAY, N.J., June 09, 2025--U.S. FDA Approves Merck’s ENFLONSIA for Prevention of RSV Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season",
    "url": "https://finnhub.io/api/news?id=209771e65ba9345db30d520f7d6de48f8a2725a527b2dc0ea0291683c501e70f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749496260,
      "headline": "U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season",
      "id": 135143066,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., June 09, 2025--U.S. FDA Approves Merck’s ENFLONSIA for Prevention of RSV Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season",
      "url": "https://finnhub.io/api/news?id=209771e65ba9345db30d520f7d6de48f8a2725a527b2dc0ea0291683c501e70f"
    }
  },
  {
    "ts": null,
    "headline": "Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials",
    "summary": "Merck & Co., Inc. (NYSE:MRK) on Monday shared topline results from the first two of three Phase 3 clinical trials evaluating the safety and efficacy of enlicitide decanoate, an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor for hyperlipidemia on lipid-lowering therapies, including at least a statin. Hyperlipidemia refers to having high levels of lipids (fats) in the blood, including cholesterol and triglycerides. It’s a condition that can increase the risk",
    "url": "https://finnhub.io/api/news?id=52d58f3b7d6dca0513b3505c68922a0d8adf5ccd59905ac0b427b48e56b13445",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749492901,
      "headline": "Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials",
      "id": 135143067,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) on Monday shared topline results from the first two of three Phase 3 clinical trials evaluating the safety and efficacy of enlicitide decanoate, an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor for hyperlipidemia on lipid-lowering therapies, including at least a statin. Hyperlipidemia refers to having high levels of lipids (fats) in the blood, including cholesterol and triglycerides. It’s a condition that can increase the risk",
      "url": "https://finnhub.io/api/news?id=52d58f3b7d6dca0513b3505c68922a0d8adf5ccd59905ac0b427b48e56b13445"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Down on Medicaid Fears -- Health Care Roundup",
    "summary": "Health Care Down on Medicaid Fears -- Health Care Roundup",
    "url": "https://finnhub.io/api/news?id=ac8f6f2f818b08df091d37084208e2e9aae1f745ae00124a0adcdc396e1103b5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749490020,
      "headline": "Health Care Down on Medicaid Fears -- Health Care Roundup",
      "id": 135152466,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Health Care Down on Medicaid Fears -- Health Care Roundup",
      "url": "https://finnhub.io/api/news?id=ac8f6f2f818b08df091d37084208e2e9aae1f745ae00124a0adcdc396e1103b5"
    }
  },
  {
    "ts": null,
    "headline": "Merck Gets FDA Approval for Respiratory Treatment for Infants",
    "summary": "By Kelly Cloonan The U.S. Food and Drug Administration has approved Merck's Enflonsia, a treatment to prevent respiratory syncytial virus lower respiratory tract disease in newborns and infants....",
    "url": "https://finnhub.io/api/news?id=e10895ac4e02aa9bcf11b0958e61ea4296219f0867f02745a75cefa542333d70",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749484868,
      "headline": "Merck Gets FDA Approval for Respiratory Treatment for Infants",
      "id": 135138278,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "By Kelly Cloonan The U.S. Food and Drug Administration has approved Merck's Enflonsia, a treatment to prevent respiratory syncytial virus lower respiratory tract disease in newborns and infants....",
      "url": "https://finnhub.io/api/news?id=e10895ac4e02aa9bcf11b0958e61ea4296219f0867f02745a75cefa542333d70"
    }
  },
  {
    "ts": null,
    "headline": "US FDA approves Merck's RSV antibody for infants",
    "summary": "The U.S. Food and Drug Administration on Monday approved Merck'spreventive antibody shot to protect infants up to one year of age from respiratorysyncytial virus during their first RSV season, the...",
    "url": "https://finnhub.io/api/news?id=f3b3a3e6550e4a37447e7acb312276b99e74293d7a09748ac3192d918135df9c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749482593,
      "headline": "US FDA approves Merck's RSV antibody for infants",
      "id": 135137965,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "The U.S. Food and Drug Administration on Monday approved Merck'spreventive antibody shot to protect infants up to one year of age from respiratorysyncytial virus during their first RSV season, the...",
      "url": "https://finnhub.io/api/news?id=f3b3a3e6550e4a37447e7acb312276b99e74293d7a09748ac3192d918135df9c"
    }
  },
  {
    "ts": null,
    "headline": "Merck Pill Lowers Cholesterol Levels. By How Much Is the Critical Point.",
    "summary": "Merck Pill Lowers Cholesterol Levels. By How Much Is the Critical Point.",
    "url": "https://finnhub.io/api/news?id=229371b416f642b82d1d31adaea53c65b3ec51f1c59192f62f27a996a7f59667",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749467280,
      "headline": "Merck Pill Lowers Cholesterol Levels. By How Much Is the Critical Point.",
      "id": 135152470,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck Pill Lowers Cholesterol Levels. By How Much Is the Critical Point.",
      "url": "https://finnhub.io/api/news?id=229371b416f642b82d1d31adaea53c65b3ec51f1c59192f62f27a996a7f59667"
    }
  },
  {
    "ts": null,
    "headline": "Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia",
    "summary": "RAHWAY, N.J., June 09, 2025--Merck Announces Positive Topline Results from Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults with Hyperlipidemia",
    "url": "https://finnhub.io/api/news?id=7b995aa80fffac22b071929a82dcf52ee984136242c57eea9646df9a689d342c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749465900,
      "headline": "Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia",
      "id": 135125115,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., June 09, 2025--Merck Announces Positive Topline Results from Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults with Hyperlipidemia",
      "url": "https://finnhub.io/api/news?id=7b995aa80fffac22b071929a82dcf52ee984136242c57eea9646df9a689d342c"
    }
  },
  {
    "ts": null,
    "headline": "Merck: positive Phase 3 results in hyperlipidemia",
    "summary": "Merck reports positive initial results from two of three Phase 3 clinical trials evaluating the safety and efficacy of enlicitide decanoate for the treatment of adults with hyperlipidemia.They met...",
    "url": "https://finnhub.io/api/news?id=684564a3fd0ef0478c4b44798f9f863c07851cb2ada07ca87070e31057a81cd1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749460108,
      "headline": "Merck: positive Phase 3 results in hyperlipidemia",
      "id": 135123626,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck reports positive initial results from two of three Phase 3 clinical trials evaluating the safety and efficacy of enlicitide decanoate for the treatment of adults with hyperlipidemia.They met...",
      "url": "https://finnhub.io/api/news?id=684564a3fd0ef0478c4b44798f9f863c07851cb2ada07ca87070e31057a81cd1"
    }
  },
  {
    "ts": null,
    "headline": "ASCO 2025: Profiling The Biggest Presentations At The Biggest Cancer Meeting",
    "summary": "ASCO 2025: Profiling The Biggest Presentations At The Biggest Cancer Meeting",
    "url": "https://finnhub.io/api/news?id=7d9a39bb88dc0d21c44233082b1b59854633e898207759f5e5520a2824199ff7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749458700,
      "headline": "ASCO 2025: Profiling The Biggest Presentations At The Biggest Cancer Meeting",
      "id": 135123455,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=7d9a39bb88dc0d21c44233082b1b59854633e898207759f5e5520a2824199ff7"
    }
  },
  {
    "ts": null,
    "headline": "Merck Cholesterol Drug Hits Main Goals in Two Phase 3 Studies",
    "summary": "By Colin Kellaher Merck & Co. said its oral PCSK9 inhibitor candidate enlicitide hit its key goals in a pair of late-stage studies in adults with high cholesterol. Merck, which is evaluating...",
    "url": "https://finnhub.io/api/news?id=5474c0bca802b3b679c68c58623b7a869c4752efb76687228b06bd4ac1a08087",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749455592,
      "headline": "Merck Cholesterol Drug Hits Main Goals in Two Phase 3 Studies",
      "id": 135122952,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Merck & Co. said its oral PCSK9 inhibitor candidate enlicitide hit its key goals in a pair of late-stage studies in adults with high cholesterol. Merck, which is evaluating...",
      "url": "https://finnhub.io/api/news?id=5474c0bca802b3b679c68c58623b7a869c4752efb76687228b06bd4ac1a08087"
    }
  },
  {
    "ts": null,
    "headline": "Merck's potential blockbuster cholesterol pill succeeds in late-stage studies",
    "summary": "Merck's oral cholesterol pillsucceeded in two late-stage studies, marking a win for thedrugmaker as it focuses on the development of growth driversbeyond its cancer drugs and vaccines. ...",
    "url": "https://finnhub.io/api/news?id=aa568487be910362ce7cd0d3ae1ee04cce8e1cacfd0b4cd92d4af71cb10f5b7b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749452895,
      "headline": "Merck's potential blockbuster cholesterol pill succeeds in late-stage studies",
      "id": 135123561,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck's oral cholesterol pillsucceeded in two late-stage studies, marking a win for thedrugmaker as it focuses on the development of growth driversbeyond its cancer drugs and vaccines. ...",
      "url": "https://finnhub.io/api/news?id=aa568487be910362ce7cd0d3ae1ee04cce8e1cacfd0b4cd92d4af71cb10f5b7b"
    }
  },
  {
    "ts": null,
    "headline": "Merck's cholesterol drug meets main goal in two studies",
    "summary": "Merck said on Monday its drugmet the main goal of reducing a type of cholesterol in twolate-stage studies. The drug, enlicitide decanoate, is being evaluated as atreatment for...",
    "url": "https://finnhub.io/api/news?id=117f83e25c98b2c2ad673e2adfac8951ed22b0a09eca225cfcc448ff80142240",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749452895,
      "headline": "Merck's cholesterol drug meets main goal in two studies",
      "id": 135122704,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck said on Monday its drugmet the main goal of reducing a type of cholesterol in twolate-stage studies. The drug, enlicitide decanoate, is being evaluated as atreatment for...",
      "url": "https://finnhub.io/api/news?id=117f83e25c98b2c2ad673e2adfac8951ed22b0a09eca225cfcc448ff80142240"
    }
  },
  {
    "ts": null,
    "headline": "Merck's cholesterol drug meets main goal in late-stage studies",
    "summary": "Merck said on Monday its drug met the main goal of reducing a type of cholesterol in two late-stage studies. ...",
    "url": "https://finnhub.io/api/news?id=7fefe716746c91ea2cafe7e9819057209749b1fcad6631e9e048aebcf4456795",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749452417,
      "headline": "Merck's cholesterol drug meets main goal in late-stage studies",
      "id": 135122632,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck said on Monday its drug met the main goal of reducing a type of cholesterol in two late-stage studies. ...",
      "url": "https://finnhub.io/api/news?id=7fefe716746c91ea2cafe7e9819057209749b1fcad6631e9e048aebcf4456795"
    }
  },
  {
    "ts": null,
    "headline": "Merck Reports Positive Phase 3 Results for Enlicitide In Treating Adults With Hyperlipidemia",
    "summary": "Merck & Co Inc: * MERCK ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE FIRSTTWOPHASE 3 CORALREEF TRIALS EVALUATING ENLICITIDE DECANOATE FOR THETREATMENT OF ADULTS WITH HYPERLIPIDEMIA ...",
    "url": "https://finnhub.io/api/news?id=957dd25186e650c16fb77e7831b58c370c1828dabf3c96ac5be6a9d7ea144aa9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749451987,
      "headline": "Merck Reports Positive Phase 3 Results for Enlicitide In Treating Adults With Hyperlipidemia",
      "id": 135122595,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck & Co Inc: * MERCK ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE FIRSTTWOPHASE 3 CORALREEF TRIALS EVALUATING ENLICITIDE DECANOATE FOR THETREATMENT OF ADULTS WITH HYPERLIPIDEMIA ...",
      "url": "https://finnhub.io/api/news?id=957dd25186e650c16fb77e7831b58c370c1828dabf3c96ac5be6a9d7ea144aa9"
    }
  }
]